Drug survival of infliximab and adalimumab in inflammatory bowel disease

被引：0
|
作者：
Asadipour, Erfan [1 ]
Kargar, Mona [2 ]
机构：
[1] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran
[2] Univ Tehran Med Sci, Res Ctr Rational Use Drugs, Tehran, Iran
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2020年 / 42卷 / 06期
关键词：
THERAPY;
D O I：
10.1007/s11096-020-01151-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1521 / 1523
页数：3
相关论文
共 50 条
  • [21] Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
    Mahmoud, R.
    Schultheiss, J.
    Louwers, J.
    van der Kaaij, M.
    van Hellemondt, B.
    Mahmmod, N.
    van Boeckel, P.
    Jharap, B.
    Fidder, H.
    Oldenburg, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S420 - S421
  • [22] Infliximab in inflammatory bowel disease
    Papamichael, Konstantinos
    Lin, Steve
    Moore, Matthew
    Papaioannou, Garyfallia
    Sattler, Lindsey
    Cheifetz, Adam S.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10
  • [23] Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients
    Bar-Yoseph, Haggai
    Blatt, Alexandra
    Gerassy, Shiran
    Pressman, Sigal
    Mousa, Amjad
    Sabo, Edmond
    Waterman, Matti
    Ungar, Bella
    Ben-Horin, Shomron
    Chowers, Yehuda
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (06): : 884 - 892
  • [24] RETROSPECTIVE STUDY OF DOSE ESCALATION WITH ADALIMUMAB, INFLIXIMAB, AND VEDOLIZUMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Zhang, K. H.
    Singh, H.
    Twardowski, R.
    Lu, C.
    Wan, Y.
    Null, K.
    VALUE IN HEALTH, 2020, 23 : S143 - S143
  • [25] False Positive Infliximab Levels Detected in Patients Treated with Adalimumab for Inflammatory Bowel Disease
    Abraham, Bincy
    Chiorean, Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S627 - S627
  • [26] Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Vande Casteele, Niels
    Abraham, Bincy P.
    Ritter, Timothy
    Jain, Anjali
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (11) : 2978 - +
  • [27] A COMPARISON OF DRUG SURVIVAL TIMES FOR INFLIXIMAB, ADALIMUMAB AND ETANERCEPT
    Pocock, Joanna M.
    Albreshni, Samir
    Slack, Ruth
    Polydoropoulou, Varvara
    O'Reilly, David
    Oestoer, Andrew J.
    RHEUMATOLOGY, 2009, 48 : I69 - I69
  • [28] Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach
    Chadokufa, S.
    Sider, S.
    Huggett, B.
    Sawney, T.
    Shah, N.
    Baycheva, M.
    Perez, A. Zambrano
    Acton, N.
    Kiparissi, F.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S381 - S382
  • [29] ANTI-DRUG ANTIBODIES (ADA): ASSAY PERFORMANCE IN PATIENTS TREATED FOR INFLAMMATORY BOWEL AND RHEUMATIC DISEASE WITH BIODRUGS, ADALIMUMAB AND INFLIXIMAB
    O'Donnell, J.
    Liu, J.
    Keating, P.
    Hock, B.
    Spellerberg, M.
    Barclay, M.
    Stamp, L.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 15 - 15
  • [30] Effectiveness of therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease patients. Systematic review and meta-analysis
    Petryszyn, P.
    Dybalski, L.
    Gola, K.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S324 - S325
12345